) and its commercial partner, Almirall S.A., presented data from
a new multiple sclerosis (MS) study on Sativex at the 29th
Congress of the European Committee for Treatment and Research in
Multiple Sclerosis (ECTRIMS).
The data showed that Sativex was effective in improving the
spasticity symptoms in patients suffering from MS in the long run
while maintaining its safety profile. While improving the
spasticity symptoms, Sativex did not impact the patients' driving
ability, cognition or mood.
We note that Sativex is already approved in 22 countries for
the treatment of spasticity due to MS.
Data from a phase IV, 50 weeks, double-blind, randomized,
placebo-controlled study showed that Sativex (average dose 6.4
spray/day) was identical to placebo both in cognition and mood
scales, and was comfortably tolerated.
Additionally, data from another prospective and observational
new study, held across centers in Germany, showed that Sativex
had no adverse impact on patients' ability to drive and
improved MS spasticity and spasms count.
We note that GW Pharma has a licencing agreement with Almirall
S.A. for Sativex. As per the agreement, Almirall has the
exclusive rights to market the drug in the European Union
(excluding the UK), EU accession countries as well as
Switzerland, Norway and Turkey. Almirall also has the rights to
market the drug in Mexico. However, GW Pharma holds the rights to
manufacture and supply Sativex to Almirall.
Sativex was also in the news last month when GW Pharma
announced about a new pricing agreement for Sativex in Germany.
As per the agreement, a mutually-acceptable reimbursement price
has been agreed upon between Almirall S.A. and the German
National Association of Statutory Health Insurance Funds
Alimirall had objected to the reduced price of Sativex
enforced by the German authorities in Mar 2013. The newly
announced agreement resolved this issue thereby resulting in an
increase in prices.
GW Pharma also filed a phase III Investigational New Drug
(IND) application with the U.S. Food and Drug Administration
(FDA) in Aug 2013 to evaluate Sativex for MS spasticity.
Meanwhile, GW Pharma is also conducting two phase III studies
on Sativex in the U.S. for treating pain in cancer patients. The
company expects top-line results from these studies by next year,
after which it will file a New Drug Application in the U.S.
GW Pharma carries a Zacks Rank #3 (Hold). Companies that
currently look well-positioned include
) with a Zacks Rank #1 (Strong Buy), and
Sarepta Therapeutics, Inc.
) with a Zacks Rank #2 (Buy).
ACTELION LTD (ALIOF): Get Free Report
GW PHARMA-ADR (GWPH): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
SAREPTA THERAP (SRPT): Free Stock Analysis
To read this article on Zacks.com click here.